JBM  Vol.6 No.8 , August 2018
The Curative HCV Treatments in China
Abstract: Hepatitis C disease is caused by hepatitis C virus (HCV) which causes chronic infections in about 180 million individuals worldwide. HCV has been identified as the etiologic agent of hepatitis C in 1989 and for the longest time it is very difficult to treat chronic carriers who are at risk of developing severe liver disease. Now there are three main combined treatments which can increase curative ratio from 10% to more than 90%. The advents of so called directly, acting antivirals (DAAs) in the last few years has revolutionized HCV treatment as these drug combinations can effectively cure HCV in the great majority of patients. The impact of DAAs on global disease burden has been limited, however, by the very drug prices. In this paper the situation was analyzed in China, Europe and Australia. DAAs have been made available to patients in Europe and Australia for several years and are generally accessible. The treatment is highly subsidized by the government, thereby making it possible for all patients in need to access therapy. DAAs have only been very recently been adopted for treatment of chronic hepatitis C in China. In our research, only the method of literature search from both Chinese websites and Foreign websites including journals, magazines and internet search is used. We analyze and compare the solutions that each of these countries is providing to their respective patient populations. Given the large number of chronic HCV carriers in China and other less developed countries solutions have to be found to produce DAAs most cost effectively.
Keywords: HCV, DAA, China, Australia, Europe
Cite this paper: Fei, Y. and Jiang, J. (2018) The Curative HCV Treatments in China. Journal of Biosciences and Medicines, 6, 42-59. doi: 10.4236/jbm.2018.68004.

[1]   Burstow, N.J., Mohamed, Z., Gomaa, A.I., Sonderup, M.W., Cook, N.A., Waked, I., et al. (2017) Hepatitis C Treatment: Where Are We Now? International Journal of General Medicine, 10, 39-52.

[2]   World Health Organization (2017) Global Hepatitis Report. Geneva.

[3]   Tyagi, I. and Koirala, J. (2017) Hepatitis C. Annals of Internal Medicine, 125, 658-668.

[4]   Ray, S.C., Bailey, J.R. and Thomas, D.L. (2013) Hepatitis C, Chapter 27. In: Knipe, D.M. and Howley, P.M., Eds., Fields Virology, Lippincott Williams & Wilkins, Philadelphia, PA, 795-824.

[5]   Seeff, L.B. (2004) Natural History of Hepatitis C. Hepatology, 51, 63-75.

[6]   Hajarizadeh, B., Grebely, J. and Dore, G.J. (2013) Epidemiology and Natural History of HCV Infection. Nature Reviews Gastroenterology & Hepatology, 10, 553-562.

[7]   Koziel, M.J. and Peters, M.G. (2007) Viral Hepatitis in HIV Infection. New England Journal of Medicine, 356, 1445-1454.

[8]   Miao, Z., Xie, Z., Miao, J., Ran, J., Feng, Y. and Xia, X. (2017) Regulated Entry of Hepatitis C Virus into Hepatocytes. Viruses, 9, 100.

[9]   Murphy, K. and Casey, W. (2016) Janeway’s Immunobiology. Garland Science/Taylor & Francis Group, LLC Print, New York, NY.

[10]   Simmonds, P., Irvine, B., Yap, P.L., Kolberg, J., Chan, S.-W., Cha, T.-A., Beall, E., Urdea, M.S., Holmes, E.C. and Mcomish, F. (1993) Classification of Hepatitis C Virus into Six Major Genotypes and a Series of Subtypes by Phylogenetic Analysis of the NS-5 Region. Journal of General Virology, 74, 2391-2399.

[11]   De, A.M., Ravera, R., Gioia, D., Gariglio, M. and Landolfo, S. (2002) The Interferon System: An Overview. European Journal of Paediatric Neurology, A41-A46, A55-A58.

[12]   Parkin, J. and Cohen, B. (2001) An Overview of the Immune System. The Lancet, 357, 1777-1789.

[13]   Fensterl, V. and Sen, G.C. (2009) Interferons and Viral Infections. Biofactors, 35, 14-20.

[14]   De Veer, M.J., Holko, M., Frevel, M., Walker, E., Der, S., Paranjape, J.M., Silverman, R.H. and Williams, B.R. (2001) Functional Classification of Interferon-Stimulated Genes Identified Using Micro-arrays. Journal of Leukocyte Biology, 69, 912-920.

[15]   Moiseeva, O., Mallette, F.A., Mukhopadhyay, U.K., Moores, A. and Ferbeyre, G. (2006) DNA Damage Signaling and p53-Dependent Senescence after Prolonged β-Interferon Stimulation. Molecular Biology of the Cell, 17, 1583-1592.

[16]   Anonymous (1997) National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology, 26, 2S.

[17]   Carithers Jr., R.L. and Emerson, S.S. (1997) Therapy of Hepatitis C: Meta-Analysis of Interferon Alfa-2b Trials. Hepatology, 26, 83S-88S.

[18]   McHutchison, J.G., Gordon, S.C., Schiff, E.R., et al. (1998) Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. Hepatitis Interventional Therapy Group. The New England Journal of Medicine, 339, 1485-1492.

[19]   European Association for Study of Liver (2011) EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection. Journal of Hepatology, 55, 245-264.

[20]   Di Bisceglie, A.M. and Hoofnagle, J.H. (2002) Optimal Therapy of Hepatitis C. Hepatology, 36, S121-S127.

[21]   European Association for Study of Liver (2015) EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology, 63, 199-236.

[22]   Antaki, N., Craxi, A., Kamal, S., Moucari, R., Van der Merwe, S., Haffar, S., et al. (2010) The Neglected Hepatitis C Virus Genotypes 4, 5 and 6: An International Consensus Report. Liver International Official Journal of the International Association for the Study of the Liver, 30, 342-355.

[23]   Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Jr., G.F., et al. (2003) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. The New England Journal of Medicine, 351, 975-982.

[24]   The American Society of Health-System Pharmacists (2016) Ribavirin.

[25]   Ortega-Prieto, A.M., Sheldon, J., Grande-Pérez, A., Tejero, H., Gregori, J., Quer, J., Esteban, J.I., Domingo, E. and Perales, C. (2013) Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis. PLoS ONE, 8, e71039.

[26]   Crotty, S., Cameron, C. and Andino, R. (2002) Ribavirin’s Antiviral Mechanism of Action: Lethal Mutagenesis? Journal of Molecular Medicine, 80, 86-95.

[27]   Fischer, J. and Ganellin, C.R. (2006) Analogue-Based Drug Discovery. John Wiley & Sons, Hoboken, 504.

[28]   Snell, N.J. (2001) Ribavirin—Current Status of a Broad Spectrum Antiviral Agent. Expert Opinion on Pharmacotherapy, 2, 1317-1324.

[29]   Hézode, C., Fontaine, H., Dorival, C., et al. (2013) Triple Therapy in Treatment-Experienced Patients with HCV-Cirrhosis in a Multicenter Cohort of the French Early Access Programme (ANRS CO20-CUPIC) NCT01514890. Journal of Hepatology, 59, 434-441.

[30]   Bruchfeld, A., Lindahl, K., Stahle, L., Soderberg, M. and Schvarcz, R. (2003) Interferon and Ribavirin Treatment in Patients with Hepatitis C—Associated Renal Disease and Renal Insufficiency. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association—European Renal Association, 18, 1573-1580.

[31]   Ward, R.P. and Kugelmas, M. (2005) Using Pegylated Interferon and Ribavirin to Treat Patients with Chronic Hepatitis C. American Family Physician, 72, 655-662.

[32]   Schinazi, R., Halfon, P., Marcellin, P. and Asselah, T. (2014) HCV Direct-Acting Antiviral Agents: The Best Interferon-Free Combinations. Liver International Official Journal of the International Association for the Study of the Liver, 34, 69.

[33]   Kwo, P.Y., Lawitz, E.J., McCone, J., et al. (2010) Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination with Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients with Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomized, Multicenter Phase 2 Trial. The Lancet, 376, 705-716.

[34]   Poordad, F., McCone, J., Bacon, B.R., et al. (2011) Boceprevir for Untreated Chronic HCV Genotype 1 Infection. The New England Journal of Medicine, 364, 1195-1206.

[35]   Jacobson, I.M., McHutchison, J.G., Dusheiko, G., et al. (2011) Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. The New England Journal of Medicine, 364, 2405-2416.

[36]   González-Moreno, J. and Payeras-Cifre, A. (2013) Hepatitis C Virus Infection: Looking for Interferon Free Regimens. The Scientific World Journal, 2013, Article ID: 825375.

[37]   Jacobson, I.M., Dore, G.J., Foster, G.R., et al. (2014) Simeprevir with Pegylated Interferon Alfa 2a plus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection (QUEST-1): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 384, 403-413.

[38]   Manns, M., Marcellin, P., Poordad, F., et al. (2014) Simeprevir with Pegylated Interferon Alfa 2a or 2b plus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection (QUEST-2): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet, 384, 414-426.

[39]   Summa, V., Ludmerer, S.W., McCauley, J.A., et al. (2012) MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants. Antimicrobial Agents and Chemotherapy, 56, 4161-4167.

[40]   Muir, A.J., Poordad, F., Lalezari, J., Everson, G., Dore, G.J., Herring, R., et al. (2015) Daclatasvir in Combination with Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection with Compensated Cirrhosis. JAMA, 313, 1736.

[41]   Lawitz, E., Poordad, F., Brainard, D.M., et al. (2013) Sofosbuvir in Combination with PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study. Hepatology, 58, 1380A.

[42]   Blumer, C., Roche, P., Spencer, J., Lin, M., Milton, A., Bunn, C., et al. (2003) Australia’s Notifiable Diseases Status, 2001: Annual Report of the National Notifiable Diseases Surveillance System. Communicable Diseases Intelligence, 27, 1-78.

[43]   Kirby Institute (2014) HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2013.

[44]   Mccaw, R., Moaven, L., Locarnini, S.A. and Bowden, D.S. (2010) Hepatitis C Virus Genotypes in Australia. Journal of Viral Hepatitis, 4, 351-357.

[45]   Hepatitis C Virus Infection Consensus Statement Working Group (2017) Australian Recommendations for the Management of Hepatitis C Virus Infection: A Consensus Statement. Gastroenterological Society of Australia, Melbourne.

[46]   (2015) About Hepatitis C.

[47]   Adam, G. (2015) Turnbull Government to Spend 1 Billion on Hepatitis C “Miracle Cures” for All.

[48]   Lucy, C. (2017) Hepatitis C Will Be Eradicated in Australia by 2026, Researchers Predict.

[49]   European Association for Study of Liver (2012) Easl Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. Journal of Hepatology, 57, 167-185.

[50]   Poordad, F., Lawitz, E., Kowdley, K., et al. (2012) 12-Week Interferon-Free Regimen of ABT-450/R+ABT-333+ Ribavirin Achieved SVR12 in More than 90% of Treatment-Naive HCV GT-1-Infected Subjects and 47% of Previous Non-Responders. Journal of Hepatology, 56, S549-S550.

[51]   Vigan, A.M., Carlo, F.P., Antonio, C., Alessio, A., Alfredo, A., Pietro, A., et al. (2017) Treatment of Hepatitis C Virus Infection in Italy: A Consensus Report from an Expert Panel. Digestive and Liver Disease, 49, 731-741.

[52]   Sciences, G. and Million, W. (2012) Gilead Sciences Announces Second Quarter 2012 Financial Results. Gilead Sciences Inc., Foster City.

[53]   (2016) Europe Approves AbbVie’s New Hepatitis C Treatment. Hepatitis News.

[54]   Sievert, W., Altraif, I., Razavi, H.A., Abdo, A., Ahmed, E.A., Alomair, A., et al. (2011) A Systematic Review of Hepatitis C Virus Epidemiology in Asia, Australia and Egypt. Liver International, 31, 61-80.

[55]   China Center for Disease Control and Prevention, Ministry of Health (2003-2012) National Official Infectious Disease Reports.

[56]   Micallef, J.M., Kaldor, J.M. and Dore, G.J. (2006) Spontaneous Viral Clearance Following Acute Hepatitis C Infection: A Systematic Review of Longitudinal Studies. Journal of Viral Hepatitis, 13, 34.

[57]   Duan, Z., Jia, J.D., Hou, J., Lou, L., Tobias, H., Xu, X.Y., et al. (2014) Current Challenges and the Management of Chronic Hepatitis C in Mainland China. Journal of Clinical Gastroenterology, 48, 679-686.

[58]   Chen, Y.D., Liu, M.Y., Yu, W.L., Li, J.Q., Peng, M., Dai, Q., et al. (2002) Hepatitis C Virus Infections and GTs in China. Hepatobiliary & Pancreatic Diseases International: HBPD INT, 1, 194-201.

[59]   Bo, F., Jin, Z. and Lai, W. (2011) Inadequate Awareness of Hepatitis C among Nonspecialist Physicians in China. Advances in Medical Education & Practice, 2, 209.

[60]   Yu, Z., Chen, L.M. and Miao, H. (2017) Hepatitis C Virus in Mainland China with an Emphasis on Genotype and Subtype Distribution. Virology Journal, 14, 41.

[61]   Zhao, S., Liu, E., Yu, H., Yang, H., Xun, M., Xue, X., Song, J., Xu, K. and Chu, Y. (2008) Comparison of Peginterferon and Interferon in Treating Chinese Patients with Chronic Hepatitis C. Hepatogastroenterology, 55, 1047-1054.

[62]   Bi, M.R., Kang, L., Zhang, K. and Yang, B.S. (2015) Clinical Significance of Different HCV GTs and Discussion about Treatment Effect of Interferin. Chinese Journal of Frontier Medical Science, 7, 76-79.

[63]   Omata, M., Kanda, T., Yu, M.L., Yokosuka, O., Lim, S.G., Jafri, W., Tateishi, R., Hamid, S.S., Chuang, W.L., Chutaputti, A., et al. (2012) APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection. Hepatology International, 6, 409-435.

[64]   Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L. and Seeff, L.B. (2011) An Update on Treatment of GT 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-1444.

[65]   Feeney, E.R. and Chung, R.T. (2014) Antiviral Treatment of Hepatitis C. BMJ, 348, g3308.

[66]   Pawlotsky, J.M. (2014) New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. Gastroenterology, 146, 1176-1192.

[67]   Chinese Society of Hepatology (2015) The Guidelines of Prevention and Treatment for Chronic Hepatitis C. Chinese Hepatology, 33, 192-194.

[68]   Hill, A., Khoo, S., Fortunak, J., Simmons, B. and Ford, N. (2014) Editor’s Choice: Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 58, 928.

[69]   Kao, J.H., Jensen, D.M., Manns, M.P., Jacobson, I., Kumada, H., Toyota, J., et al. (2016) Daclatasvir plus Asuna-previr for HCV Genotype 1b Infection in Patients with or without Compensated Cirrhosis: A Pooled Analysis. Liver International, 36, 954.